1,575 results on '"Krueger, James G."'
Search Results
302. IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells
303. Clinical Clearing of Psoriasis by 6-Thioguanine Correlates With Cutaneous T-Cell Depletion via Apoptosis: Evidence for Selective Effects on Activated T Lymphocytes
304. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions
305. The Majority of Epidermal T Cells in Psoriasis Vulgaris Lesions can Produce Type 1 Cytokines, Interferon-γ, Interleukin-2, and Tumor Necrosis Factor-α, Defining TC1 (Cytotoxic T Lymphocyte) and TH1 Effector Populations:1 a Type 1 Differentiation Bias is also Measured in Circulating Blood T Cells in Psoriatic Patients
306. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
307. 312-nanometer Ultraviolet B Light (Narrow-Band UVB) Induces Apoptosis of T Cells within Psoriatic Lesions
308. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis
309. Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis
310. Cutaneous p38 mitogen-activated protein kinase activation triggers psoriatic dermatitis
311. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis
312. The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease
313. The skin as an immune organ: Tolerance versus effector responses and applications to food allergy and hypersensitivity reactions
314. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
315. Contribution of fibroblasts to tunnel formation and inflammation in hidradenitis suppurativa/ acne inversa
316. Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis
317. A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti–interleukin 17A/F nanobody, in moderate-to-severe psoriasis
318. A systematic review and critical evaluation of immunohistochemical associations in hidradenitis suppurativa
319. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab
320. Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases
321. Inflammasome Signaling and Impaired Vascular Health in Psoriasis
322. Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients
323. Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature
324. Hyperspectral imaging in automated digital dermoscopy screening for melanoma
325. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
326. Atopic dermatitis endotypes and implications for targeted therapeutics
327. Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms
328. Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation
329. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab
330. Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin
331. A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa
332. A systematic review and critical evaluation of immunohistochemical associations in hidradenitis suppurativa
333. Trimethylpsoralen Bath PUVA Is a Remittive Treatment for Psoriasis Vulgaris: Evidence That Epidermal Immunocytes Are Direct Therapeutic Targets
334. Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17(TIA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis
335. Sunlight-induced Basal Cell Carcinoma Tumor Cells and Ultraviolet-B-irradiated Psoriatic Plaques Express Fas Ligand (CD95L)
336. Thalidomide Induces Granuloma Differentiation in Sarcoid Skin Lesions Associated with Disease Improvement
337. Narrowband UV-B Produces Superior Clinical and Histopathological Resolution of Moderate-to-Severe Psoriasis in Patients Compared With Broadband UV-B
338. Identification of Aberrantly Regulated Genes in Diseased Skin Using the cDNA Differential Display Technique
339. SARS‐CoV‐2 receptor ACE2 protein expression in serum is significantly associated with age.
340. The erythema Q‐score, an imaging biomarker for redness in skin inflammation.
341. MAGEA3 Expression in Cutaneous Squamous Cell Carcinoma Is Associated with Advanced Tumor Stage and Poor Prognosis
342. Modulation of epidermal differentiation, tissue inflammation, and T-lymphocyte infilitration in psoriatic plaques by topical calcitriol
343. Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes
344. The Insulin-like Growth Factor 1 Receptor Is Expressed by Epithelial Cells with Proliferative Potential in Human Epidermis and Skin Appendages: Correlation of Increased Expression with Epidermal Hyperplasia
345. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis
346. Potential Role of the Chemokine Receptors CXCR3, CCR4, and the Integrin αEβ7 in the Pathogenesis of Psoriasis Vulgaris
347. Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation.
348. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis.
349. Tape strips from early‐onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin.
350. Human Keratinocytes Are a Major Source of Cutaneous Platelet-derived Growth Factor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.